Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Drug Profile

Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Alternative Names: DF-277; Durasert™ three-year uveitis insert; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal insert; Iluvien; Injectable micro-insert - pSivida; Medidur; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/pSivida

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; Johns Hopkins University; pSivida Inc
  • Class Anti-inflammatories; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic macular oedema
  • Phase III Uveitis
  • No development reported Dry age-related macular degeneration; Retinal vascular occlusion; Wet age-related macular degeneration

Most Recent Events

  • 13 Mar 2017 Fluocinolone acetonide micro-insert intravitreous implant licensed to Brill Pharma in Spain
  • 22 Feb 2017 Preregistration for Diabetic macular oedema in Canada (Intravitreous)
  • 22 Feb 2017 Health Canada accepts New Drug Submission for fluocinolone acetonide implant (Iluvien®) for Diabetic macular oedema for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top